|
丸子 一朗
Department School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine Position Associate Professor |
|
| Article types | Original article |
| Language | English |
| Peer review | Peer reviewed |
| Title | Subfoveal choroidal thickness after brolucizumab therapy for neovascular age-related macular degeneration: a short-term multicenter study. |
| Journal | Formal name：Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie Abbreviation：Graefes Arch Clin Exp Ophthalmol ISSN code：1435702X/0721832X |
| Domestic / Foregin | Foregin |
| Volume, Issue, Page | pp.--- |
| Author and coauthor | Tamashiro Tamaki, Tanaka Koji, Itagaki Kanako, Nakayama Makiko, Maruko Ichiro, Wakugawa Sorako, Terao Nobuhiro, Onoe Hajime, Wakatsuki Yu, Ogasawara Masashi, Sugano Yukinori, Yamamoto Akiko, Kataoka Keiko, Izumi Takahiko, Kawai Moeko, Mori Ryusaburo, Sekiryu Tetsuju, Okada Annabelle A, Iida Tomohiro, Koizumi Hideki, |
| Publication date | 2022/01 |
| Summary | BACKGROUND/PURPOSE:Observation of choroidal thickness after anti-vascular endothelial growth factor (VEGF) therapy may be important for the ideal management of neovascular age-related macular degeneration (AMD). This study investigated changes in subfoveal choroidal thickness (SCT) during loading doses of intravitreal injections of brolucizumab in eyes with neovascular AMD.METHODS:This study included 73 eyes of 72 patients with neovascular AMD at five university hospitals in Japan. All 73 eyes underwent three monthly 6.0 mg intravitreal injections of brolucizumab at baseline, 1 month, and 2 months. The SCT at 3 months was evaluated using optical coherence tomography.RESULTS:The 73 eyes were classified into the treatment-naïve group (43 eyes) and the switched group (30 eyes) that were switched from other anti-VEGF treatments. After three intravitreal injections of brolucizumab, SCT significantly decreased from 236.5 ± 98.8 µm at baseline to 200.4 ± 98.3 µm at 3 months (percent of baseline 84.7%, P < 0.001) in the treatment-naïve group. In the switched group, SCT also significantly decreased from 229.0 ± 113.2 μm at baseline to 216.9 ± 110.2 μm at 3 months (percent of baseline 94.7%, P = 0.039), although the decrease was not as marked compared to that of the treatment-naïve group.CONCLUSION:Intravitreal injections of brolucizumab for neovascular AMD significantly reduced the SCT in both the treatment-naïve and switched groups. Brolucizumab may cause significant anatomic changes in the choroid, particularly in treatment-naïve AMD eyes, possibly more than that previously reported for other anti-VEGF agents. |
| DOI | 10.1007/s00417-021-05517-1 |
| PMID | 35034215 |